Johnson & Johnson Plans $1B+ Divestiture of Cerenovus Stroke Care Business

Feb 12, 2025 19:09 CST Updated 19:09

Johnson & Johnson

Medical Device R&D and Manufacturer

On February 12, the Financial Times of the UK published重磅消息,Johnson & JohnsonPlanning to$1 billion(approximately equivalent toRMB 7.3 billion) to sell itsCerenovus Stroke Business。

Johnson & Johnson "has reached out to potential private equity and strategic buyers through advisors to test interest in Cerenovus"interest." Two sources who wished to remain anonymous estimated its potential valuation atBetween $1 billion and $1.5 billion。

Johnson & Johnson Considers SaleCerenovus, the most important reason is still forBy divesting businesses, optimizing product portfolios, and focusing on flagship brands, Johnson & Johnson reshapes its growth engine.。

Over the past year, following the complete divestiture of its consumer health division, Johnson & Johnson has undertaken a series of actions, including corporate brand renewal and major acquisitions. A "new Johnson & Johnson" is now fully focused on two key areas: innovative pharmaceuticals and medical technology.

Innovative Drugs，In September 2024, Johnson & Johnson statedCardiovascular and Metabolism Department of Innovative Pharmaceuticals BusinessThis is at least the second major restructuring for Johnson & Johnson's innovative pharmaceuticals division after announcing the closure of its infectious diseases and vaccines unit in 2023.

In Medical TechnologyIn addition to integrating its five major medical technology sub-brands (Ethicon, DePuy Synthes, etc.) under "Johnson & Johnson Medical Technologies" to streamline the structure and enhance competitiveness, Johnson & Johnson also acquired Shockwave Medical for $13.1 billion to strengthen its cardiovascular intervention technology, while exiting the consumer products business.

This sale of Cerenovus isDouble the investment in innovation-intensive niche markets while divesting non-core assets that do not align with its long-term strategy.Another Major Initiative。

It is worth noting that:In 2017,Johnson & Johnson established Cerenovus, its neurovascular business unit, through the acquisition of Pulsar Vascular and Neuravi. It also integrated a series of previously acquired neurointervention-related companies such asCodman NeuroBusiness integration.

Thus, Cerenovus has become an important brand for Johnson & Johnson in the neurovascular business sector, and is part of the DePuy Synthes division under Johnson & Johnson Medical Technology.

Reports reveal: Cerenovus business lacks growth potential in the future, prompting Johnson & Johnson to consider divestment.Cerenovus Business。

Currently, the sale of the Cerenovus business is still at the rumor stage, with no official confirmation yet. We will continue to monitor the developments.

· END ·

--Featured Recommendations--